Chen P, Chen J, Zheng Q, Chen W, Wang Y, Xu X
While monthly GLP-1 formulations may become commercially available soon in higher-income regions, other geographies especially those with high expected biosimilar penetration may continue relying on weekly-dosed drugs for the foreseeable future
According to obesity treatment guidelines, patients should demonstrate approximately 5% weight loss after 12 weeks at the maintenance dose to continue therapy
Climate change and global warming have exacerbated the risk of chronic aflatoxins exposure, affecting approximately five billion people worldwide, particularly in the developing countries [7,8,9]
On average, participants had been on treatment for about nine months and were followed for roughly eight months after they stopped
In vitro assays confirmed their specific activity towards glutathione, with relevant kinetic parameters